Overview
AIM market data
Price History
AIM price chart
Valuation & Profitability
No Valuation Data Yet
Alpha Vantage and Twelve Data both returned no valuation metrics for AIM. Check back after the next daily valuation refresh — this symbol may be new, delisted, or temporarily unavailable from both providers.
Company news
AIM ImmunoTech Outlines Upcoming Milestones, Including DURIPANC Primary Endpoint Analysis Expected In December 2026Benzinga · Jun 24, 2026, 12:40 PM
AIM ImmunoTech Doses Final Patient In Phase 2 Trial Of Ampligen For Treatment Of Metastatic Pancreatic Cancer In Combination With AstraZeneca's Imfinzi; Topline Results Expected Q1 2027Benzinga · Jun 18, 2026, 1:15 PM
AIM ImmunoTech Regains NYSE ComplianceBenzinga · Jun 15, 2026, 12:15 PM
8-K filing — AIM ImmunoTech Inc. (AIM)SEC EDGAR · Jun 15, 2026, 12:01 PM
AIM ImmunoTech Commences ~$2.65M Registered Direct Offering Of 2.554M Common Shares At $0.5189/ShareBenzinga · Jun 9, 2026, 1:40 PM
AIM ImmunoTech Files Prospectus For Resale Of Up To 31,287,933 SharesBenzinga · Jun 8, 2026, 8:15 PM
AIM ImmunoTech Reports Positive Phase 2 DURIPANC Update As Final Patient Enrolled In Pancreatic Cancer TrialBenzinga · Jun 8, 2026, 12:45 PM
U.S. State Dept Announces Nearly $38M In Additional Funding Toward The Department's Ongoing Ebola Response EffortsBenzinga · Jun 5, 2026, 6:30 PM
AIM ImmunoTech Shares Resume Trade Following Circuit Breaker HaltBenzinga · Jun 1, 2026, 4:19 PM
AIM ImmunoTech Enrolls Final Participant In Its Phase 2 Clinical Study Of Ampligen Combined With AstraZeneca's Anti-PD-L1 Immune Checkpoint Inhibitor Imfinzi To Treat Metastatic Pancreatic CancerBenzinga · Jun 1, 2026, 1:00 PM